Skip to content

Esketamine for depression: all studies

Page 29 of 57: studies 281 to 290 of 564, newest first. Back to the esketamine for depression overview

Research

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.

CNS Spectrums January 17, 2025 Roger S McIntyre, Gregory W Mattingly, Yordan Godinov et al. 9 citations

Esketamine nasal spray (ESK) is approved in combination with an oral antidepressant (OAD) for the treatment of adults with treatment-resistant depression (TRD); however, direct comparisons with atypical antipsychotics for TRD are limited. This secondary analysis of the ESCAPE-TRD study compared rates of remission and response, and improvements in depressive symptoms over time, between ESK and...

DOI: 10.1017/S1092852924002451 (opens in new tab) Full text (opens in new tab) Major depressive disorder Quetiapine Remission Treatment-resistant depression trd +6

Myelin Repair as a Novel Mechanism for Ketamine's Sustained Antidepressant Effects.

Current Neuropharmacology January 16, 2025 Sen Wang, Chaoli Huang, Mengyu Wang et al. 4 citations

Depression is a prevalent mental disorder, affecting approximately 300 million people worldwide. Despite decades of research into the underlying mechanisms of depression, a consensus remains elusive. Recent studies have implicated changes in oligodendrocytes and myelin in the pathogenesis of depression. Conventional antidepressants may alleviate symptoms within weeks of use, but approximately...

DOI: 10.2174/011570159X349856241213144902 (opens in new tab) Full text (opens in new tab) Arketamine Depression Esketamine Enantiomer +6

Effects of subanesthetic repeated esketamine infusions on memory function and NGF in patients with depression: An open-label study.

Journal of Affective Disorders January 15, 2025 Qiongyao Yang, Yitan Yao, Xiaoping Yuan et al. 3 citations

Subanesthetic ketamine is a rapidly acting antidepressant, yet the effects of ketamine on cognitive function are inconsistent. The primary objective of this study was to explore the effects of esketamine on memory function and plasma levels of nerve growth factor (NGF) in patients with depression. A total of 132 patients with depression completed six intravenous esketamine infusions (0.4 mg/kg)...

DOI: 10.1016/j.jad.2024.09.162 (opens in new tab) Full text (opens in new tab) Major depressive disorder Antidepressant Cognition Nerve growth factor +5

Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study.

Journal of Affective Disorders January 15, 2025 Fernanda Palhano-Fontes, Patrícia Cavalcanti-Ribeiro, Kaike Thiê da Costa Gonçalves et al. 7 citations

Ketamine has gained prominence as one of the most effective therapeutic options in unipolar treatment-resistant depression (TRD). However, most studies related to the antidepressant action of ketamine used intravenous (IV) or intranasal (IN) administration. The subcutaneous (SC) route of administration is a promising alternative, as it results in plasma levels comparable to IV, causes fewer...

DOI: 10.1016/j.jad.2024.09.141 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Subcutaneous Unipolar depression Depression treatment +3

Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study

CNS Spectrums 2025 Ana Rodríguez Lorente, María Pilar Campos-Navarro, Ángela Gil Montoya et al.

Abstract Objectives This proof-of-concept study aimed to assess the impact of intranasal esketamine (ESK-IN) in brain volume and neurofilament light chain (sNfL) over 6-months in patients with treatment resistant depression (TDR). Methods Seven TRD patients received ESK-IN while continuing oral antidepressants. Clinical evaluations were conducted at baseline, 1, 3, and 6 months, with MRI scans...

DOI: 10.1017/s1092852925100631 (opens in new tab)

Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression.

Frontiers in Psychiatry 2025 Alexandre Fraichot, Sophie Favre, Hélène Richard-Lepouriel 1 citation

Intranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry. This case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and...

DOI: 10.3389/fpsyt.2025.1536232 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression Artificial intelligence Case report Intranasal esketamine

Spravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile.

Neuropsychiatric Disease and Treatment 2025 Ahmed Asad Raza, Ghazi Uddin Ahmed, Habiba Zafar et al. 6 citations

Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) are debilitating psychiatric conditions associated with significant psychosocial and economic burdens. Conventional antidepressants, particularly SSRIs and SNRIs, often produce inadequate responses and cause sexual dysfunction, contributing to poor adherence and diminished quality of life. This review aims to evaluate the...

DOI: 10.2147/ndt.s548944 (opens in new tab) Full text (opens in new tab) Esketamine Major depressive disorder Spravato Treatment-resistant depression +1

Personalizing esketamine treatment in TRD and TRBD: the role of mentalization, cognitive rigidity, psychache, and suicidality.

Frontiers in Psychiatry 2025 Miriam Olivola, Filippo Mazzoni, Barbara Tarantino et al. 7 citations

Treatment-Resistant Depression (TRD) remains a major challenge in the management of Major Depressive Disorder (MDD). Esketamine, the S-enantiomer of ketamine and a glutamatergic modulator, was approved by the FDA and EMA for TRD in 2019. Beyond its rapid antidepressant effects, esketamine may enhance neuroplasticity, facilitating the reconnection with emotional and cognitive processes,...

DOI: 10.3389/fpsyt.2025.1736114 (opens in new tab) Full text (opens in new tab) Esketamine Major depressive disorder Treatment-resistant depression Cognitive rigidity +2

The perspectives of patients with depression toward esketamine, and the influence of their medication adherence on their viewpoints: a Saudi cross-sectional study.

Frontiers in Psychiatry 2025 Ahmad H Almadani, Ayedh H Alghamdi, Fahad B Alfahad et al.

Nasal esketamine has demonstrated efficacy in the management of treatment-resistant depression and psychiatric emergency due to major depression. This study investigates acceptance and awareness of esketamine as a depression treatment option, focusing on factors that influence patients' acceptance, including adherence to current medication regimens, regardless of prior esketamine exposure. This...

DOI: 10.3389/fpsyt.2025.1678119 (opens in new tab) Full text (opens in new tab) Depression Esketamine Saudi arabia Perspectives +1